Showing results (211-220 of 245) with videos related to
Sort By:
Pageof 25
Cancer Research Communications|June 25, 2025
A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 YearsEric D Eisenmann, Ronan Swords, Ying Huang, et al.Blood Advances|July 17, 2023
Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratoriesUma Borate, Fei Yang, Richard Press, et al.Blood Neoplasia|June 17, 2026
Bone marrow immunosuppressive states associate with survival after guadecitabine and atezolizumab therapy in HMA-R/R MDSH Josh Jang, Guillermo Urrutia, Andreas Due Ørskov, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 10, 2016
A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid LeukemiaIvana Gojo, Jan H Beumer, Keith W Pratz, et al.The Lancet. Haematology|November 12, 2022
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trialJustin M Watts, Maria R Baer, Jay Yang, et al.Journal for Immunotherapy of Cancer|August 30, 2023
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.Blood|April 7, 2021
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 resultsBijal D Shah, Michael R Bishop, Olalekan O Oluwole, et al.Leukemia|March 20, 2025
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.Cancer|August 23, 2021
Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)Hagop M Kantarjian, Kebede H Begna, Jessica K Altman, et al.The New England Journal of Medicine|October 31, 2019
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AMLAlexander E Perl, Giovanni Martinelli, Jorge E Cortes, et al.Pageof 25